tiprankstipranks
Advertisement
Advertisement

IBIO Stock Latest News

Validating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition
RatingsValidating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition
17d ago
IBIO
iBio Advances to Clinical Stage With IBIO-600 Trial
PremiumCompany Announcements
iBio Advances to Clinical Stage With IBIO-600 Trial
18d ago
8K
IBIO
iBio receives regulatory clearance to initiate IBIO-600 trial in Australia
PremiumThe Fly
iBio receives regulatory clearance to initiate IBIO-600 trial in Australia
18d ago
IBIO
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
27d ago
ACOG
IBIO
Insiders Rock Asana, Ibio, Redwire, AFLAC, Sibanye Stillwater
PremiumWeekend Updates
Insiders Rock Asana, Ibio, Redwire, AFLAC, Sibanye Stillwater
29d ago
AFL
RDW
iBio (IBIO-610): Validated Activin E Mechanism, Strategic Trial Positioning, and Attractive Risk-Reward Support a Buy Rating
PremiumRatingsiBio (IBIO-610): Validated Activin E Mechanism, Strategic Trial Positioning, and Attractive Risk-Reward Support a Buy Rating
1M ago
IBIO
Buy Rating on iBio Driven by Differentiated Activin-Targeting Antibody and Large PH-HFpEF Market Opportunity
Premium
Ratings
Buy Rating on iBio Driven by Differentiated Activin-Targeting Antibody and Large PH-HFpEF Market Opportunity
1M ago
IBIO
iBio to provide update on cardiopulmonary program
Premium
The Fly
iBio to provide update on cardiopulmonary program
1M ago
IBIO
Buy Rating on iBio Driven by Promising IBIO-610 Obesity Data and Favorable Risk-Reward Profile
PremiumRatings
Buy Rating on iBio Driven by Promising IBIO-610 Obesity Data and Favorable Risk-Reward Profile
2M ago
IBIO
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential
PremiumCompany Announcements
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential
2M ago
8K
IBIO
iBio announces new preclinical data from study evaluating IBIO-610
PremiumThe Fly
iBio announces new preclinical data from study evaluating IBIO-610
2M ago
IBIO
iBio initiated with a Buy at JonesResearch
PremiumThe Fly
iBio initiated with a Buy at JonesResearch
2M ago
IBIO
Ibio Ends At-The-Market Equity Offering Program
PremiumCompany AnnouncementsIbio Ends At-The-Market Equity Offering Program
2M ago
8K
IBIO
iBio files $200M mixed securities shelf
Premium
The Fly
iBio files $200M mixed securities shelf
2M ago
IBIO
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
IBIO
iBio: Differentiated Activin E Obesity Pipeline and Strengthened Balance Sheet Underpin Buy Rating
PremiumRatings
iBio: Differentiated Activin E Obesity Pipeline and Strengthened Balance Sheet Underpin Buy Rating
2M ago
IBIO
iBio reports Q2 EPS (9c), consensus (6c)
PremiumThe Fly
iBio reports Q2 EPS (9c), consensus (6c)
2M ago
IBIO
iBio files to sell 11.06M shares of common stock for holders
PremiumThe Fly
iBio files to sell 11.06M shares of common stock for holders
3M ago
IBIO
iBio Announces Private Placement to Fund Pipeline Expansion
PremiumCompany Announcements
iBio Announces Private Placement to Fund Pipeline Expansion
3M ago
8K
IBIO
iBio prices 11.06M shares at $2.35 in private placement
PremiumThe FlyiBio prices 11.06M shares at $2.35 in private placement
4M ago
IBIO
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
4M ago
IBIO
Mechanistic Validation of Activin E Targeting De-Risks IBIO-610 and Supports Buy Rating on iBio Shares
Premium
Ratings
Mechanistic Validation of Activin E Targeting De-Risks IBIO-610 and Supports Buy Rating on iBio Shares
4M ago
IBIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >